United Therapeutics
NYSE/NASDAQ:UTHRBiotechResearch Triangle Park, North Carolina, United States · Est. 1996 · 2,700 employees
United Therapeutics develops and commercializes innovative therapies for pulmonary hypertension, cystic fibrosis, and other life-threatening diseases.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
83
Clinical Trials↗
All sponsored trials (all statuses)
26
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 34
Phase 22
Preclinical2
By Therapeutic Area
top 3
Respiratory
229%
Cardiovascular
229%
Nephrology
114%
R&D Momentum
40/100
Pipeline Velocity
11/100
Trial Completion Rate
58/100
Pipeline Concentration
27/100
Pipeline Freshness
36/100
Strategic Signals
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 10, 2026
Recruiting
EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)
Sep 8, 2026
8-K
FORM 8-K
Earlier
Sep 4, 2026TrialAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)
Aug 5, 20268-K8-K
Jul 23, 20268-KFORM 8-K
Jul 14, 2026TrialA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Jul 7, 2026TrialA Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Jun 29, 20268-KFORM 8-K
Details
Company Info
Company Overview
$14.5B
Mkt Cap
$1.6B
Revenue
$1.7B
Cash
CEOMartine Rothblatt
Founded1996
Employees2,700
HQResearch Triangle Park, North Carolina, United States
ExchangeNYSE/NASDAQ:UTHR
Websiteunitedhealthcare.com
LinkedInCompany Page
Therapeutic Focus
OtherOncologyCardiovascularRespiratoryImmunologyMetabolic & EndocrineNephrology
Recent SEC Filings
8-KSep 8, 2026
FORM 8-K
8-KAug 5, 2026
8-K
8-KJul 23, 2026
FORM 8-K
8-KJun 29, 2026
FORM 8-K
EX-99.1Mar 9, 2026
UNITED THERAPEUTICS Corp (UTHR) (CIK 0001082554)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Nephrology
Respiratory
Cardiovascular
Nephrology
ESRD
GGTA1 KO ThymokidneyPreclinical
Respiratory
Unknown / Other
Efficacy and Safety
RalinepagPhase 3
Safety and Efficacy
GGTA1 KO ThymokidneyPreclinical
Regulatory
Regulatory Timeline
20091 event
FDAJul 30
Remodulin — TYVASO
Application NDA022387 (NDA)
20131 event
FDADec 20
Orenitram — ORENITRAM
Application NDA203496 (NDA)
20151 event
FDAMar 10
Unituxin — UNITUXIN
Application BLA125516 (BLA)
20181 event
FDAJul 30
Remodulin — REMODULIN
Application NDA208276 (NDA)
20221 event
FDAMay 23
Remodulin — TYVASO DPI
Application NDA214324 (NDA)
20231 event
FDASep 28
Remodulin — REMODULIN
Application NDA021272 (NDA)
20251 event
FDAMay 23
Remodulin — YUTREPIA
Application NDA213005 (NDA)
20265 events
SECSep 8
FORM 8-K
Accession: 0001104659-26-105953
SECAug 5
8-K
Accession: 0001082554-26-000028
SECJul 23
FORM 8-K
Accession: 0001104659-26-086068
SECJun 29
FORM 8-K
Accession: 0001104659-26-078865
SECMar 9
UNITED THERAPEUTICS Corp (UTHR) (CIK 0001082554)
Accession: 000-26301
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)